Advaxis, Inc.

General Information

(Note: Advaxis, Inc. withdrew its plan for a NASDAQ uplisting – a unit offering of stock and warrants – in an SEC filing dated June 27, 2022. The company did not intend to list the warrants on the NASDAQ. Advaxis filed an S-1 on May 12, 2022, for the public offering in connection with the NASDAQ uplisting of its stock from the OTCQX. The public offering price of $3.70 was the last reported sale of its common stock on the OTCQX Best Market under the symbol “ADXSD” as of June 8, 2022. **The board of directors approved a reverse stock split at a ratio of one-for-80, which took effect on June 6, 2022.)

We are a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen-presenting cells (“APCs”) to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor micro-environment, or TME, to enable the T cells to attack tumor cells.

We believe that its current pipeline evaluating off-the shelf, neoantigen-directed immunotherapies (i.e., our HOT program) can address significant unmet needs in the current oncology treatment landscape. Specifically, our first drug construct from the HOT program is ADXS-503 (HOT Lung), which has been designed to treat non-small cell lung cancer (NSCLC); it has the potential to optimize checkpoint inhibitors’ performance in NSCLC, while having a generally well-tolerated safety profile.

On July 15, 2021, the Company announced the initiation of a Phase 1 clinical study evaluating the second drug construct from our HOT program, ADXS-504 (HOT Prostate), in patients with biochemically recurrent prostate cancer. The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504 for the treatment of early prostate cancer.

Industry: Pharmaceuticals
Employees: 15
Founded: 1987
Contact Information
Address 9 Deer Park Drive, Suite K-1 Monmouth Junction, New Jersey
Phone Number (609) 452-9813
Web Address
View Prospectus: Advaxis, Inc.
Financial Information
Market Cap $15.98mil
Revenues $ mil (last 12 months)
Net Income $ mil (last 12 months)
IPO Profile
Symbol ADXS
Exchange NASDAQ
Shares (millions): 2.5
Price range $3.70 - $3.70
Est. $ Volume $9.3 mil
Manager / Joint Managers A.G.P.
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change